Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), filed a Form 4 on November 19, 2026, disclosing the automatic sale of 107 shares of common stock on November 17, 2026, to satisfy mandatory tax withholding obligations upon the vesting of restricted stock units.
Key Highlights
- Reporting person: Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc.
- Transaction: 107 shares of common stock disposed of (transaction code S) on November 17, 2026.
- Price: Weighted average price of $1.45 per share, reflecting a pro rata allocation from a broker sale of 4,070 shares on behalf of a group of employees.
- Purpose: Shares were sold automatically to satisfy mandatory tax withholding requirements upon vesting of restricted stock units.
- Remaining ownership: Peterson directly beneficially owned 17,926 shares of common stock following the transaction.
- Filing date: November 19, 2026, signed by Adam D. Levy as Attorney-in-Fact.
Tax Withholding Sale Details for Acrivon Therapeutics CAO Peterson
According to the Form 4 filed with the SEC, Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc., disposed of 107 shares of common stock on November 17, 2026. The filing states that the shares were "sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units," classifying the transaction under code S.
The filing further explains that the $1.45 price per share "reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person." The proceeds of all such sales were described as allocated "to the employees, including the reporting person, on a pro rata basis." Peterson's 107 shares represent her pro rata portion of that group transaction.
Following the reported transaction, the filing indicates Peterson directly beneficially owned 17,926 shares of Acrivon Therapeutics common stock. No derivative securities transactions were reported. The form was filed by one reporting person and was signed by Adam D. Levy as Attorney-in-Fact on November 19, 2026.
What Was Disclosed
Acrivon Therapeutics Chief Accounting Officer Katharine Peterson reported the automatic sale of 107 common shares at a weighted average price of $1.45 on November 17, 2026, solely to cover mandatory RSU vesting tax obligations, leaving her with 17,926 directly held shares.



Please wait processing your request...